IT IS KNOWN THAT THE ENDOCRINE system has a tight interrelationship with the circadian clock, but available information is still insufficient to fully interpret this relation. For example, the regulatory role of growth hormone secretagogues (GHSs) and their receptors (GHSR), a newly found branch of the endocrine system, on the circadian clock is still elusive. GHSs are known to have effects on many physiological activities, including pituitary hormone secretion, pancreatic endocrine, gastric acid secretion, regulation of appetite, energy metabolism, and cardiovascular functions (6, 13, 16, 33, 46, 47) . Some investigators reported that GHSs could also influence the circadian rhythm and sleeping, but their findings are inconsistent or even contradictory. For example, ghrelin is reported to decrease rapid eye movement sleep duration (41) but promote slowwave sleep in humans (45) . However, both central administration and microinjection of ghrelin into forebrain induce wakefulness in rodents (38, 39) . Another example is that growth hormone releasing peptide (GHRP)-2 does not affect sleep in humans (26) , whereas ghrelin and GHRP-6, respectively, induce phase advance in cultured suprachiasmatic nuclei (SCN) and in mice under food deprivation (50) . These inconsistent observations suggest that the roles of GHSs in circadian rhythm and sleeping still need extensive studies, given that the regulation of circadian rhythm and sleeping share some similar mechanisms.
Mammalian circadian rhythms are controlled by a master clock located in the hypothalamic SCN (21) and are entrained principally by the environmental light (27) . Moreover, some nonphotic stimuli, such as feeding (22) , ambient temperature (2) , daily periods of induced activity (29) , and certain hormones such as melatonin (34) and ghrelin (50) can also regulate the circadian rhythm. Among the nonphotic zeitgebers, ghrelin, the endogenous ligand of GHSR, and its analogs, such as GHRP-6, could induce phase advance at both in vitro and in vivo conditions (50) . These findings suggest that GHSs may impact the circadian system, except for their effects on other physiological activities. Under in vivo conditions, phase advance implies earlier arousal and activities while phase delay means the opposite. Depending on the circadian window of sensitivity to resetting cues (4), a modulator of rhythmicity (zeitgeber) may induce either phase advance or phase delay, or no phase shift (dead zone), at certain circadian times (CTs). When discussing the impact of GHSs on the circadian rhythm, a critical question is whether GHSs, as potential nonphotic zeitgebers, would impact the circadian rhythm, and if yes, what is actually the effect.
Some earlier studies (38, 39, 50) suggest that GHSs induce phase advance of the circadian rhythm. In the present study, however, we for the first time showed that GHRP-6 induced phase delay of the circadian locomotor activities in freerunning mice at a special time of day (CT12) but did not induce obvious phase shift at other CTs either at ad libitum or under food deprivation, and even at a large dose. Our unique findings suggest that GHSs may exert an otherwise unusual action on the circadian system. We further investigated the underlying signaling mechanisms by which GHRP-6 induces phase delay and found that GHRP-6 used a similar signaling pathway of light-induced phase delay at early night (12) , involving calcium/calmodulin-dependent protein kinase II (CaMKII), cAMP response element-binding protein (CREB), period 1 (Per1), and prokineticin 2 (PK2) (52) . Our findings may help to unveil new roles of GHSs in the regulation of the circadian clock.
MATERIALS AND METHODS

Animals and recording of locomotor activity.
A total of 165 male C57BL/6J mice, age 5-6 wk and body weight 20 Ϯ 2 grams, were purchased from the Experimental Animal Center, Chinese Academy of Medical Sciences. All animals were housed individually in plastic cages (45 ϫ 25 ϫ 20 cm) equipped with a running wheel (diameter 11.5 cm) in each cage. Every four cages were put into a lightcontrolled box, and all of the boxes were placed in a light-and temperature-controlled room (25 Ϯ 1°C). Regular chow and water were provided routinely. Animals were subjected to volunteer running-wheel activities first to entrain a 12:12-h light-dark (LD) cycle (white fluorescent light, 150 lux, light on at 0600, off at 1800) for 2 wk and then were released into constant dark (DD). The locomotor activity of animals under DD showed a typical "free-running" circadian rhythm roughly of 23.5 h. Here, CT (i.e., the time of day) was used to indicate the clock times at DD, CT12 was defined as the beginning of subjective night, which is usually the onset time of locomotor activity, and CT0/24 was usually the time of activity offset. Signals of locomotor activities were continuously acquired by the VitalView Data Acquisition System (Mini-Mitter). Animals were killed after the wheel-running experiments, and SCN tissues were harvested for further laboratory studies. Data analyses were performed by the ActiView Biological Rhythm Analysis software (n ϭ 6 for each checked CT point). Efforts were made to minimize animal suffering and the number of animals used. The animal use protocol was approved by the Life Ethics Committee of Peking Union Medical College and was conducted in compliance with the U.S. National Institutes of Health (NIH) Guidelines for the Care and Use of Laboratory Animals (NIH Publication 85-23).
Drug administration. To access the effect of GHRP-6 on the phase of circadian locomotor rhythms, intraperitoneal injection of GHRP-6 (100 g/kg dissolved in 200 l saline) was performed at different CT points (n ϭ 6 for each CT). The dark experiments were performed under a dim red light (3-4 lux). The same volume of saline was injected in the same way serving as controls (n ϭ 4 for each CT).
Intracerebroventricular injection. Four additional mice underwent intracerebroventricular injection to deliver phosphorylated CREB (p-CREB) antibody to the lateral ventricles, aiming to observe the potential involvement of p-CERB in the action of GHRP-6 on circadian rhythm in the SCN. To perform the intracerebroventricular procedure, mice that had adapted to LD and DD cycles each for at least 1 wk were put out of the cage and underwent the intracerebroventricular injection procedure under a dim red light as mentioned above. Animals were anesthetized with 20% urethane hydrate (1.3 g/kg ip) (Sigma-Aldrich) and placed in a stereotaxic apparatus (Reward Scientific Technology). The skull bone was exposed after incision of the skin. A small hole (diameter 1 mm) was made perpendicularly to the skull with a skull drill (Reward Scientific Technology) at the site of Ϫ0.46 mm anterior and 1.1 mm lateral to the bregma. A stainless steel guide cannula (internal diameter, 0.48 mm; length, 0.8 cm) was then slowly and vertically inserted in the hole (depth 2.3 mm from the skull surface) to reach the lateral ventricle. Cerebrospinal fluid efflux from the cannula was considered a success of lateral ventricle cannulation. The cannula mouth was quickly sealed with the equipped needle core, and the guide cannula was fixed in place by dental cement. The scalp was sutured, and the animal was allowed to recover for 1 wk at LD before turning to DD adaptation for 2 wk ready for next intracerebroventricular injection.
Recording of SCN neuron discharge in vivo. Twelve mice were used to observe the time-dependent effects of GHRP-6 on SCN neuron discharge in vivo (n ϭ 6 for both CT6 and CT12), with respective baseline discharges as self-controls. Mice were anesthetized with 20% urethane hydrate (1.3 g/kg ip; Sigma-Aldrich) and mounted on a stereotaxic apparatus (Reward Scientific Technology). Supplemental doses of urethane hydrate were used to prevent any nociceptive reaction to pinching of the hindpaw. Body temperature was maintained at 37°C throughout the experiments using a water heating pad. A burr hole of 1 mm in diameter, 0.46 mm posterior to the bregma, 0.15 mm lateral to the midline, and 5.5-5.8 mm depth from the brain surface was made for electrodes to reach the SCN areas and to record the firing of SCN neurons. Extracellular unitary recordings of SCN neuronal firing (extracellular potentials) were conducted using glass microelectrodes filled with 2 M NaCl and with a sampling frequency of 32 kHz. The electrode impedance was 10 -15 M⍀. Firing frequency was analyzed using a BL-420E data acquisition system (Taimeng Software, Chengdu, China) and a customized program for calculation of descriptive statistics.
SCN tissue sampling. SCN tissues were harvested for examining the effects of GHRP-6 on the levels of intraneuronal free Ca 2ϩ ([Ca 2ϩ ]i), glutamate (Glu), and ␥-aminobutyric acid (GABA) and the expression levels of GHSR, phosphorylated CaMKII (p-CaMKII), p-CREB, and clock genes in the SCN. The time between GHRP-6 administration and animal death/SCN sampling depended on the purpose of each subset experiment and was indicated in the descriptions of each experimental method (below). For example, to observe the phase-shifting effects of GHRP-6 on the circadian locomotor rhythms, SCN tissues were harvested at different CTs after the running-wheel experiments; to observe the acute effect of GHRP-6 on [Ca 2ϩ ]i, Glu, and GABA, SCN tissues were harvested 30 min after GHRP-6 injection. Because most of the in vivo experiments were performed under DD, to obtain the SCN tissues, mice were killed by decapitation under a dim red light of 3-4 lux (a light intensity that is believed insufficient to stimulate retina ganglial cells). Next, the global brain was harvested by sterile scalpel. To dissect the SCN from brain, leptomeningeal blood vessels were removed, and a SCNcontaining robust brain slice (thickness 400 m) containing the hypothalamus regions was made with a vibratome. Next, SCN tissues were captured by a thin-wall steel punch with the hatch of the punch shaped to the size and appearance of the SCN. The harvested SCN tissues were either freshly used or stored at Ϫ80°C for later laboratory study. Some brains were fixed with inverse infusion of 4% formalin via the left ventricle before decapitation, and the brain was then developed for immunohistochemical (IHC) staining. The time needed for each sampling was controlled within 1-2 min.
Flow cytometry to measure [Ca 2ϩ ]i of isolated SCN neurons. Sixteen mice were used to examine the CT-dependent Ca 2ϩ -mobilizing effect of GHRP-6 on SCN neurons, with saline as control (n ϭ 4 both for GHRP-6 and saline). Mice were adapted to an LD cycle for 7 days and then switched to DD circumstance for 10 days, followed by GHRP-6 administration at CT12 and CT6. Thirty minutes after GHRP-6 administration, animals were killed, SCN were harvested, and SCN neurons were isolated to observe [Ca 2ϩ ]i levels of the SCN neurons. To isolate SCN neurons, the fresh SCN tissues were minced with 0.125% trypsin solution at 37°C for ϳ10 min with occasional manual shaking, the trypsin solution was drawn off, and tissues were washed with DMEM. Such an enzymatic dissociation procedure was repeated three times. All of the collected solutions were centrifuged (1,000 g, 10 min), and the upper layer of cells (neurons were estimated presenting in this layer) was harvested and passed through a 20-m Nitex filter and then resuspended in DMEM. High-performance liquid chromatography. Nine mice were used to evaluate the effects of GHRP-6 (n ϭ 3) on SCN Glu and GABA levels, with Glu and GABA changes by short light exposure (150 lux, 15 min) (n ϭ 3) and saline (n ϭ 3) as positive and negative controls. To perform the high-performance liquid chromatography (HPLC) assay, animals were killed 30 min after GHRP-6 administration (100 g/kg ip at CT12), and SCN tissues were harvested immediately. The fresh SCN tissues were homogenized in ice-cooled buffer (0.1 M HCl, 0.1 mM sodium metabisulfate) and centrifuged at 12,000 rpm for 10 min. One hundred microliters of the supernatant were obtained and further separated by a 0.2-m pore size filter (Millipore). The filtrate was further centrifuged at 12,000 rpm for 10 min. Levels of Glu and GABA in the filtrate were separated and quantified by the HPLC procedure. The HPLC machine (Waters AccQ·Tag Amino Acid HPLC Analysis system) was equipped with Waters 510 HPLC pumps and a Waters 470 Scanning Fluorescence Detector (Millipore).
Real-time RT-PCR. Fifty two mice were used for real-time RT-PCR (RT-qPCR) assay to determine the SCN transcription levels and circadian oscillation patterns of the clock genes (Bmal1 and Per1) and the clock-controlled gene PK2. To observe the effects of KN-93 and p-CREB antibody on GHRP-6-induced per1 transcriptions, KN-93 or p-CREB antibody was given at CT11.5, and GHRP-6 was given at CT12; animals were killed at CT12.5. To observe the effects of GHRP-6 (100 g/kg ip at CT12) on the circadian transcription pattern of per1, animals were killed at different CT points after GHRP-6 administration. SCN tissues were immediately isolated, frozen by liquid nitrogen, and then homogenated in Trizol reagent solution. The total RNA of SCN tissues was extracted with Trizol reagent (Invitrogen) and quantified by absorbance at 260 nm. The reaction volume of reverse transcription polymerase chain reaction (RT-PCR) was 25 l, and the reaction temperature was set at 42°C for 30 min. Singlestrand cDNA was made from 1 g of total RNA by reverse transcription using oligo(dT) primers. Relative quantitative real-time PCR was performed on a sequence detection system (Prism 7000) and SYBR Green PCR Master Mix (Applied Biosystems). PCR was performed using primers specific for mouse Bmal1, Per1, PK2, and ␤-actin. Briefly, in each assay, both ␤-actin (used as a housekeeping control) and target genes from the same samples were amplified in duplicate in separate tubes. The mRNA levels of each gene were calculated using the relative standard curve method, normalized against the corresponding ␤-actin mRNA level, and then expressed as relative change over control. A single dissociation peak was detected in each reaction by the dissociation curve. The sequences of tested genes were downloaded from GeneBank, and the primers were designed using the Primer Express version 1.5 software (Applied Biosystems) (Bmal1: forward 5=-TGGCCGCTGTAGACACTACATT and reverse 5=-CTC-TATCCAGTAAGCTTCACAGACTGTAA, Per1: forward 5=-TC-GAAACCAGGACACCTTCTCT and reverse 5=-GGGCACCCC- GAAACACA, PK2: forward 5=-TTTCCCTGTTTATGTTTTGCCT and reverse 5=-CAGATTGTTCCCTCTTATTCTCCTA, and ␤-actin: forward 5=-TCAAGATCATTGCTCCTCCTGAG and reverse 5=-CT-GCTTGCTGATCCACATCTG). The results are the averages of three independent experiments at each time point.
IHC staining and semiquantitative morphometry. Twenty four mice were used to observe the effects of GHRP-6 on the protein expression of GHSR, p-CAMKII, p-CREB, circadian locomotor output cycles kaput (Clock), Bmal1, Per1, and PK2 in the SCN. To observe the effects of GHRP-6 on the expressions of p-CaMKII, p-CREB, and Per1, SCN tissues were harvested 30 min after GHRP-6 administration (at CT12). To observe the effects of GHRP-6 (100 g/kg ip at CT12) on the expressions of Bmal1, Clock, and PK2, SCN tissues were harvested at CT12 the next day. To observe the effects of GHRP-6 (100 g/kg ip at CT12) on the expressions of GHSR, Per1, and PK2, animals were killed 1 or 2 h after GHRP-6 administration (at CT12). To perform tissue processing, dissected brain slices containing the SCN regions were immediately fixed with formalin, routinely developed, and embedded in paraffin wax. Five-micrometer sections were cut and mounted on slides. Sections were deparaffinized, rehydrated, and then reacted with a 3% hydrogen peroxide/methanol solution to inactivate endogenous peroxidase, followed by a final 5-min wash with phosphate buffer solution (PBS).
To perform IHC stains, the avidin-biotin complex (ABC) method was used. Briefly, tissue sections were treated with Retrieve-All-1 (Signet Laboratories, Dedham, MA) for 10 min at 90°C and then washed with PBS after being cooled down at room temperature. To reduce nonspecific staining, sections were incubated with serum-free protein block (DAKO) for 10 min. The sections were then incubated with respective primary antibodies against GHSR (1:300; Santa Cruz Biotechnology), p-CAMKII (1:1,000; Abcam), p-CREB (1:100; Santa Cruz Biotechnology), Clock (1:800; Calbiochem), Bmal1 (1:200; Santa Cruz Biotechnology), Per1 (1:600; Calbiochem), and PK2 (1:200; Santa Cruz Biotechnology) for 1 h, and then incubated with biotinylated secondary antibodies (ZSGB-BIO) and ABC/horseradish peroxidase (ZSGB-BIO) for 30 min each at room temperature, with PBS wash in between. The immunoreactive products were visualized by the liquid diaminobenzidine substrate-chromogen system (ZSGB-BIO) and showed a yellow-brown color for positive stains. The sections were then rinsed with water for 5 min, dehydrated through a graded alcohol series, and mounted. Parallel control experiments were conducted by omitting the primary antibody. Specific staining signals were analyzed by a researcher blinded to the experimental design using a BI-2000 Medical Image Analysis System (Taimeng Software) that was equipped with a UB-200i microscope, CMOS camera (Epix), and BI-2000 image analysis software. To determine the global distribution of a target protein in the SCN, images were captured with the camera. Density analyses of immunolabeled cells in the SCN areas of both sides were conducted using the software with fixed threshold settings for each batch of IHC assays. Stains above the threshold were considered positive signals. Signal densities were expressed as the mean fold change relative to that of saline control. Two consecutive slides were checked for each animal, and a total of three animals were examined for each target protein.
Data analysis. Calculation of phase shift and construction of phase response curve (PRC).
We analyzed the phase-resetting ability of GHRP-6 according to the reported method (15) . Briefly, mice were entrained to a 12:12-h LD cycle before being released into DD, in which mice displayed stable free-running rhythms. Next, GHRP-6 pulses were given at variant CTs. To quantify the phase shift induced by bolus GHRP-6, regression lines were drawn through 10 -12 activity onsets before (Fig. 1A) and through 10 -12 onsets after (Fig. 1A ) the GHRP-6 pulse. The horizontal distance between the two regression lines corresponds to the phase shift triggered by GHRP-6. PRC was plotted according to values of phase shift at different CTs under DD and was used to reflect the time dependency of phase shift in response to GHRP-6 stimulation.
Data were presented as means Ϯ SD. Student's t-tests or ANOVA procedures were performed for comparison of group differences where necessary. The criterion for statistical significance was P Ͻ 0.05. Fig. 2 . Statistical phase response curve (PRC) of free-running mice in response to GHRP-6 stimulation at different CTs. Note that GHRP-6 provoked a phase delay (negative value) at CT12 but did not at other tested CTs (CT6, CT14, CT18, and CT22); n ϭ 6 for each CT. The subpanels on top are examples of the corresponding actograms. Filled triangles indicate the time points of GHRP-6 injection.
RESULTS
Bolus GHRP-6 administration induces time-dependent phase delay by activating GHSR in mice with free running. We first assessed whether GHRP-6 would induce a phase shift of the running-wheel activity in mice under DD. Bolus administration of GHRP-6 at CT12 (the beginning of subjective night) induced an obvious phase delay (Fig. 1A) while saline did not (Fig. 1B) . This phase-delay effect of GHRP-6 was totally abolished by pretreatment with D-(ϩ)-Lys-GHRP-6 (a GHSR blocker, 100 g/kg ip at CT11.5) (Fig. 1C) , whereas D-(ϩ)-Lys-GHRP-6 itself could not induce the phase shift (Fig. 1D) . Figure 1E showed the quantitative values of phase shift at different conditions.
We also examined if bolus GHRP-6 (100 g/kg ip) could induce a similar phase shift at other CTs. Figure 2 showed that bolus GHRP-6 induced a significant phase shift at CT12 but not at other checked CT points (CT6, CT14, CT18, and CT22). Figure 2 , bottom, shows the statistical PRC. In addition, bolus GHRP-6 shortly and reversibly suppressed the running-wheel activities, and this effect was not restricted to certain CT points ( Figs. 1 and 2) .
We also examined if larger-dose GHRP-6 (50 g/mouse) given at CT6 would induce phase advance in food-deprived but not in ad libitum-fed mice as observed in a previous report (50) . The results turned out that treatment with GHRP-6 this way did not induce significant phase shift either in ad libitumfed mice or in food-deprived mice (data not shown). To exclude the potential influence of experimental conditions on the phase, we carefully compared the animal strain, route, time, and dosage of drug administration and lighting conditions between the present study and a previous report (50) . Almost all of these parameters are the same except that, in Yannielli's study, only a larger-dose GHRP-6 was used, and the administration was performed at CT6 -8 (DD) under dim red light without indication of light intensity, whereas in the present study both a smaller dose (at multiple CTs) and larger dose (at CT6) was administrated under dim red light of 3-4 lux. It is likely that the different outcomes of the two studies were not due to differences of experimental conditions. GHRP-6 induces calcium mobilization and increases the excitability of SCN neurons, but decreases the SCN levels of Glu and GABA. Given the central role of calcium signaling in SCN circadian timekeeping (31), we speculated that GHRP-6 may influence the clock via affecting the calcium dynamics and the excitability of SCN neurons. To address this hypothesis, SCN neurons were isolated 30 min after systemic administration of GHRP-6 at CT12 and CT6, and [Ca 2ϩ ] i were measured. As expected, GHRP-6 given at CT12 triggered a significant Fig. 3 . Effects of GHRP-6 on the intraneuronal free Ca 2ϩ ([Ca 2ϩ ]i) levels and discharges of suprachiasmatic nuclei (SCN) neurons, and on the glutamate (Glu) and ␥-aminobutyric acid (GABA) levels of SCN. A: flow cytometry results showing that GHRP-6 at CT12 induced Ca 2ϩ mobilization, but not obviously at CT6, in SCN neurons. **P Ͻ 0.01 (n ϭ 4 in each group). B: high-performance liquid chromatography (HPLC) assay indicating that GHRP-6 decreased both Glu and GABA levels, whereas short light exposure significantly increased the Glu level but did not significantly affect the GABA level of SCN. **P Ͻ 0.01 (n ϭ 3 in each group). C and D: in vivo extracellular recordings of SCN neuronal discharges showing the effect of GHRP-6 on SCN neuronal firing at different CTs. Note that GHRP-6 given at CT12 gradually increased the discharge, and this effect reached a peak 53 min after GHRP-6 injection and then suddenly diminished. This effect was less when GHRP-6 was given at CT6 (n ϭ 4) than at CT12 (n ϭ 4). elevation of [Ca 2ϩ ] i for about two times that of the saline control (Fig. 3A) , whereas this calcium-mobilizing effect was obviously less when GHRP-6 was given at CT6 (Fig. 3A) . We then recorded the spontaneous firing of SCN neurons in vivo. Compared with the baseline, bolus systemic GHRP-6 induced a gradual increase in SCN neuronal firing frequency, and the firing reached a peak 53-54 min after GHRP-6 administration and then rapidly declined (Fig. 3C) . However, the same dose of GHRP-6 given at CT6 induced less SCN neuron firing (Fig.  3D ) compared with that at CT12 (P Ͻ 0.05). These results indicate that the phase-shifting GHRP-6 evokes a CT-dependent Ca 2ϩ mobilization and also a CT-dependent and relatively long-lasting change in the excitability of SCN neurons.
Because the phase-delay effect of GHRP-6 on locomotor rhythm at CT12 is similar to the photic phase-shifting phenomenon at early night, we compared the effects of GHRP-6 and short light exposure on the release of neurotransmitters Glu and GABA in the SCN in vivo. A light pulse (150 lux for 15 min) given at CT12 significantly elevated Glu secretion (Fig. 3B ) but did not significantly affect the secretion of GABA (Fig.  3B) , whereas GHRP-6 intraperitoneally at CT12 decreased the secretions of both Glu and GABA 30 min after administration (i.e., SCN sampled at CT12.5) (Fig. 3B) . It has been shown that light exposure at early night increases the Glu (12) and GABA levels in the SCN, although the GLUergic and GABAergic neurons associated with the circadian system originate from (KN-93) , whereas KN-93 alone given at CT11.5 did not induce a phase shift. Diamonds and asterisk represent the injection times of KN-93 (CT11.5) and GHRP-6 (CT12), respectively. C-E: immunohistochemical (IHC) stains of p-CaMKII in the SCN. SCN tissues were harvested at CT12.5 (i.e., 30 min after GHRP-6 or saline injection). Note that GHRP-6 significantly increased the level of p-CaMKII compared with saline control, whereas KN-93 pretreatment blocked this reaction. F: fold change of p-CaMKII level (with the control value as 100%) for IHC assays. **P Ͻ 0.01 (n ϭ 3 for each treatment). different retina-SCN tracts (28) . The present results showed that GHRP-6 decreased the SCN levels of Glu and GABA, whereas light exposure increased Glu but did not significantly affect the GABA level, suggesting that the signaling pathway by which GHRP-6 induces phase delay was likely different from that of light at least at the level of Glu and GABA neurotransmission, but this possibility needs further careful identification.
GHRP-6 induces phosphorylations of CaMKII and CREB and stimulates Per1 expression in the SCN, and these effects contribute to GHRP-6-induced phase delay. It is known that Ca 2ϩ binds to calmodulin and forms a Ca 2ϩ -calmodulin complex; the latter induces phosphorylation of CaMKs (including CaMKII) via the calmodulin kinase cascades (20) . The phosphorylated (activated) CaMKII in turn phosphorylates and activates the transcription factor CREB at Ser 133 (18) . The p-CREB binds to cAMP response element (CRE) and promotes the transcription of certain clock genes such as per1 (40), thus modulating the circadian rhythm of SCN. Knowing that GHRP-6 could induce Ca 2ϩ transient in SCN neurons (Fig.  3A) , we attempted to pharmacologically identify if GHRP-6 induces phosphorylations of CaMKII and CREB, stimulates per1 transcription in the SCN, and thus leads to clock phase delay. KN-93 (an antagonist of CaMKII) was given (ip) at CT11.5, GHRP-6 was given (ip) at CT12, and animals were killed at CT12.5. The results showed that pretreatment with KN-93 (30 g/kg) for 30 min abolished the phase-delay effect of GHRP-6 given at CT12 (Figs. 4A and 5B) compared with GHRP-6 alone (Figs. 4A and 5B), whereas KN-93 alone had no effect on the free-running rhythm (Figs. 4B and 5B). The IHC staining showed that GHRP-6 (ip at CT12) significantly increased the expression of p-CaMKII in SCN (Fig. 4, D and F) compared with the saline control (Fig. 4, C and F) . KN-93 pretreatment abolished the stimulating effect of GHRP-6 on CaMKII phosphorylation (Fig. 4, E and F) . These results suggest that CaMKII phosphorylation was involved in GHRP-6-induced phase delay.
In addition, GHRP-6 induced CREB phosphorylation, and this effect was also involved in the phase-shifting effect of GHRP-6. GHRP-6 (ip) induced a phase delay of the locomotor activity (Fig. 5, A and B) . Blocking the activity of p-CREB by intracerebroventricular injection of p-CREB antibody (at CT11.5) abolished the phase-delay effect of GHRP-6 in the same animal (Fig. 5, A and B) . Nine days after the first injection of p-CREB antibody (the effect of p-CREB antibody was supposedly gone), a second intracerebroventricular injection of p-CREB antibody did not produce a phase shift (Fig.  5A ), indicating that p-CREB antibody itself could not affect the locomotor rhythm but could abolish the phase-delay effect of GHRP-6 by neutralizing p-CREB.
We then examined the effect of GHRP-6 on the p-CREB level in the SCN by IHC staining. Animals were treated with GHRP-6 or saline (ip at CT12) and were killed by decapitation 30 min later (i.e., at CT12.5). Basal p-CREB-immunoreactivity (p-CREB-ir) was low at CT12.5 (i.e., 30 min after saline icv injection) in the SCN (Fig. 5, D and E) . However, the p- CREB-ir level increased rapidly in response to GHRP-6 stimulation (Fig. 5, D and F) . These results suggest that GHRP-6 can induce CREB phosphorylation, and this effect is tightly associated with the phase-delay effect of GHRP-6 at CT12 (Fig. 5, A and B) .
We further observed the effect of GHRP-6 on per1 expression at both the mRNA and protein levels. The RT-qPCR results showed that GHRP-6 (ip) injection at CT12 induced a rapid and significant elevation of per1 transcription (Fig. 5C ) compared with the saline control (Fig. 5C) . Systemic application of KN-93 or intracerebroventricular injection of p-CREB antibody both significantly suppressed the stimulating effect of GHRP-6 on per1 transcription (Fig. 5C) , whereas KN-93 or p-CREB antibody themselves did not significantly affect per1 transcription (Fig. 5C) . Accordingly, the IHC stains showed that GHRP-6 (ip at CT12) soon (within 30 min) (i.e., SCN tissues were harvested at CT12.5) induced an elevation of Per1 protein expression in the SCN (Fig. 5, D and H) compared with the saline control (Fig. 5, D and G) . These results suggest that GHRP-6 stimulated Per1 expression by inducing phosphorylations of CaMKII and CREB.
GHRP-6 phase delays the circadian oscillations of clock, Bmal1
, and PK2 expressions in the SCN. The transcription factor Clock/Bmal1 heterodimer is the core component of the molecular clock machinery in the SCN (17) , and PK2 is a clock-controlled gene and a candidate of SCN output molecule that regulates circadian locomotor behavior (52) . To investigate the involvements of Clock, Bmal1, and PK2 in the phase-shifting effect of GHRP-6, we measured the circadian transcription and protein expression of these genes by RTqPCR and IHC. When stable free-running behavior was established under DD, mice received bolus injection of GHRP-6 (100 g/kg ip) or saline at CT12. The RT-qPCR results showed that Bmal1 mRNA level was higher at the subjective night and lower at the subjective day (Fig. 6A) , whereas PK2 mRNA level was higher at the subjective day and lower at the subjective night (Fig. 6B) . These results were consistent with previous reports. In addition, the circadian oscillation rhythms of Bmal1 and PK2 were slightly phase delayed by GHRP-6, as shown by the right shift of expression curves and the time differences of transcription peaks of the two genes (Fig. 6, A  and B) . The IHC results (Fig. 6 , C-F) were consistent with the Fig. 6 . Effects of GHRP-6 on the circadian expressions of Bmal1 and prokineticin 2 (PK2) in SCN. A and B: RT-qPCR results showing that GHRP-6 delayed the transcriptional peaks of Bmal1 and PK2, respectively. C: statistical fold changes of Bmal1, circadian locomotor output cycles kaput (Clock), and PK2 protein levels (with the control value as 100%) for IHC assays. *P Ͻ 0.05 and **P Ͻ 0.01 (n ϭ 3 for each treatment). D, E, and F: representative IHC stains of Bmal1, Clock, and PK2 in the SCN, respectively. SCN samples were harvested 24 h after GHRP-6 injection at CT12. Note that GHRP-6 treatment for 24 h decreased the protein levels of Bmal1 and Clock (possibly caused by expression phase delay) but increased the level of PK2 compared with saline control; these results were in concordance with the RT-qPCR outcomes at the specific CT12.
RT-qPCR results showing that SCN Clock and Bmal1 protein levels were both lower in GHRP-6-treated animals than saline control at the critical CT12 the next day, whereas PK2 protein level was much higher in GHRP-6-treated animals than saline control animals at CT12 the next day. These GHRP-6-induced changes of Clock, Bmal1, and PK2 at CT12 the next day might be caused by the expression phase delay of these proteins.
GHRP-6 affects the expressions of GHSR, Per1, and PK2 in the SCN. The IHC staining showed that GHSR was expressed in the SCN before GHRP-6 administration (Fig. 7A) . GHRP-6 administration (at CT12) for 1 h decreased the GHSR level, whereas the GHSR level was restored 2 h after GHRP-6 administration (Fig. 7, A and D) . Basal (before GHRP-6 stimulation) Per1 expression level was low in the SCN (Fig.  7B, left) . GHRP-6 administration at CT12 significantly increased the Per1 protein expression (Fig. 7B, middle and right) . PK2 expression level was very low before GHRP-6 administration (Fig. 7C, left) . GHRP-6 administration at CT12 significantly increased the PK2 expression in the SCN, especially 2 h after GHRP-6 injection (Fig. 7C, middle and right) . Figure  7D gives the semiquantitative data of GHRP-6-induced protein fold changes relative to controls.
DISCUSSION
The major findings of this study were that systemic administration of GHRP-6 at CT12 induced phase delay in mice with free running but could not induce phase shift at other CTs even with a larger dose and/or under food deprivation, a phenomenon that is different from a previous report (50) . This difference is not likely due to the difference of experimental conditions. To our knowledge, this is the first report to show that GHSs may produce an unconventional effect on the circadian clock. Therefore, the significance of this study is to open up a new scope regarding the roles of GHSs in the circadian system. We further demonstrated that GHRP-6 partially shared the signaling pathway by which light induces phase delay at early night (Ca 2ϩ -CaMPKII-CREB-Per1) (12) ; an exception was that GHRP-6 at the beginning of subjective night decreased the SCN levels of Glu and GABA while light exposure at early night increases them (12) .
In previous studies, nonphotic stimuli are capable of producing large phase advance of the locomotor activity rhythms by downregulating the expressions of Per1 and Per2 in the SCN when applied during the subjective day in DD (3, 36, 48) . These nonphotic stimuli also decrease light induction of Per in Fig. 7 . IHC assay showing the protein expressions of GHSR, Per1, and PK2 in the SCN and effects of GHRP-6. A, GHSR. B, Per1. C, PK2. D: semiquantitative fold changes of protein expression levels (with the control value as 100%) after GHRP-6 administration (ip at CT12). *P Ͻ 0.05 and **P Ͻ 0.01 (n ϭ 3 for each protein).
the SCN at night (10, 14, 19, 49) . As mentioned above, ghrelin induces phase advance of Per1 expression at a cellular level, and GHRP-6 treatment at CT6 did not induce phase shift in ad libitum-fed mice but induced phase advance in food-deprived mice under DD (50) . Despite these reports, no study was conducted to carefully check the circadian window of GHSs action. In the light-on and light-off time points, ghrelin induces wakefulness and suppresses slow wave sleep 30 min after administration in rats (41) , whereas an opposite result shows that ghrelin promotes slow-wave sleep in humans (45) . These contradictions appear not due to experimental conditions, including species difference, but imply that GHSs have complicated and not yet elucidated effects on the circadian rhythm and the sleep control system. Based on the above thought, we investigated the potential clock-resetting actions of GHSs (GHRP-6 in the present study) at multiple CT points. To our surprise, we detected a phenomenon that is totally different from a previous observation (50) in terms of phase shifting. We further found that the phaseshifting effect of GHRP-6 is highly restricted to certain CT points, an action that is similar with short light exposure at darkness (37) but is more restrictive to the circadian window of sensitivity than light. This finding may be the second significance of the study.
The third physiological significance of this study is that we may provide a potential association among the GHS actions on circadian clock, energy conservation, and sleep regulation. GHSs are well known to stimulate GH release (16) , appetite (42) , and body weight gain in cachexia (32, 47) . These effects suggest that GHSs are capable of stimulating anabolism. This is important especially in pathological conditions with increased catabolism such as burn, inflammation, and cachexia. Because wheel-running activity closely mimics the sleep-wake rhythm, the present findings are in coincidence with the finding that GHSs (ghrelin) promote sleep in humans (45) and mice (GHRP-6 in the present study). The phase delay (likely a promotion of sleep) and attenuation of running-wheel activity induced by GHRP-6 may reduce energy consumption and be conducive to positive energy balance and body resistance to oxidative injury. Based on this point, the present study may suggest a new link among the GHS/GHSR axis, circadian clock, and energy metabolism.
Some studies have shown that behavioral immobilization also evokes phase delays during the early subjective night in hamsters (24, 43) . Because GHRP-6 induced both phase delay and suppression of locomotor activities, there may be a possibility that the phase delay effect of this agent is associated with its activity-suppressing effect. However, we showed here that the phase-delay effect of GHRP-6 was tightly bound to CT12, but the activity-suppressing effect was not restricted to CT12. Therefore, the phase-delay effect is not likely owing to its immobilizing effect, although we cannot totally exclude the possibility.
To explore the underlying mechanisms of GHS-induced phase delay, we first demonstrated that this action was mediated by GHSR because blocking GHSR by D-(ϩ)-Lys-GHRP-6 totally abolished the phase-delay effect of GHRP-6. This result may indirectly rule out the involvement of an alternative GHRP-6 binding site CD36 (7) in the regulation of the circadian clock. GHSR is extensively expressed in the brain, including the SCN (the present study), arcuate nucleus (25) , and several other hypothalamic nuclei (53) . These nuclei are the primary hypothalamic targets of GHSs. We further showed that the SCN expressions of GHSR, Per1, and PK2 exhibited a rapid (within 1-2 h) change in the SCN in response Fig. 8 . Schematic representation of the putative signaling pathways underlying the phase-delay effect of GHSs based on the present study and related reports. As a member of GHSs, GHRP-6 activates the GHSR of SCN neurons, triggers Ca 2ϩ transient, and thus induces phosphorylation of CaMKII. The p-CaMKII then phosphorylates CREB, and p-CREB enters the nucleus, binds to CRE, and induces transcription of per1. The cytoplasmic Per1/Cry complex enters into the nucleus and promotes the formation of Clock/Bmal1 heterodimers. Clock/Bmal1 heterodimers bind to the E-box of PK2 promoter and induces PK2 expression. PK2 is secreted into extracellular space, finally influences the locomotor activity, and results in phase delay.
to GHRP-6 stimulation (Fig. 7) , suggesting that GHSR, Per1, and PK2 have communications in the SCN.
We then examined the postreceptor signaling cascades by which GHRP-6 affects the circadian clock. SCN Ca 2ϩ mobilization is required for circadian clock control of behavior (23) . After binding to GHSR, GHRP-6 triggers Ca 2ϩ mobilization in SCN neurons, followed by phosphorylation of CaMKII and CREB (at Ser 133 ), and a rapid upregulation of Per1. p-CREB can activate the CREs of a number of genes, including the per1 gene (9) . A brief light pulse to free-running animals during their subjective night can rapidly induce p-CREB in the SCN and reset the phase of circadian behavioral cycles (11) . We show that these signaling cascades were causally associated with GHRP-6-induced clock resetting, because blocking CaM-KII with KN-93 or neutralizing p-CREB with the respective antibody both abolished Per1 elevation and the phase-delay effect of GHRP-6. P-CREB was induced only at CTs when the clock is sensitive to phase resetting by light, Glu, and NO (8).
Our results also support that p-CREB induction has similar sensitive windows in response to nonphotic cues such as GHRP-6, since GHRP-6 stimulates CREB phosphorylation leadingly at CT12, and the sharp upregulation of per1 transcription was observed at the very beginning of subjective night, a phenomenon similar to light stimulation (35, 54) . It should be pointed out that we performed the dark experiments (drug injection procedures) under the dim red light (3-4 lux). Although a red light with this intensity is believed insufficient to stimulate retinal ganglial cells, we still cannot rule out the possibility that a possible role of light contamination was involved.
Of note is the alteration of Per1 and PK2 expressions in response to GHS stimulation; per1 gene transcription is driven by CRE and also controlled by Clock/Bmal1 heterodimers. As a transcription factor, Per1 may affect the expression and function of Clock/Bmal1 and leads to expression of PK2 (48) . We show that GHRP-6 induced circadian phase delays of Bmal1, Per1, and PK2 expressions. Therefore, the CRE-mediated induction of Per1 is very important in the phase-shifting effect of GHRP-6. The mechanisms may involve a combination of both photic mirror image and nonphotic mechanisms. Taken together, our study suggests the presence of circadian window of sensitivity to GHSs and the reciprocal signaling used by photic and nonphotic cues in inducing clock resetting.
PK2 is a first-order clock-controlled gene in the SCN, and its expression is regulated by Clock/Bmal1 acting on the E-boxes in the gene's promoter (5) . There are E-box motifs on the PK2 promoter, and Clock/Bmal1 heterodimer can bind to the E-box and promote PK2 transcription (51) . GHRP-6 postponed the circadian phase and upregulated the PK2 level, and PK2 inhibits the locomotor wheel-running activity (5) . Therefore, PK2 may be the final effecter by which GHRP-6 induces phase delay and suppression of locomotor activity. PK2 can also depolarize target neurons and leads to enhanced cell excitability (5); this action may explain the increased SCN neuron discharge after GHRP-6 application as observed in this study. Figure 8 gives a summary of the putative signaling pathway underlying the phase-delay effect of GHRP-6 based on the present study and other reports.
We noticed that GHRP-6 had influences on Glu and GABA levels in the SCN that are different from the effects of light. Because Glu is released by the axonal terminals of retinal ganglial cells that reach the SCN through the retinohypthalamic tract in response to light (12, 44) , the reduction of SCN Glu level by GHRP-6 may suggest a suppressing action of GHS on retina-SCN Glu neurotransmission. GABA is released by a retina-originated, multisynaptic pathway, and the GABAergic fibers (together with neuropeptide Y fibers) innervate the SCN from the ventral lateral geniculate nucleus and the thalamic intergeniculate leaflet (12, 28) . GHRP-6 decreased the SCN GABA level while light did not, suggesting a differential role of GHS/GHSR in this multisynaptic pathway compared with that of light, but further investigation is needed to confirm this possibility.
In conclusion, GHRP-6, a member of GHSs, induces a CT-dependent phase delay of the circadian locomotor rhythms, and its sensitivity window is even more constrictive than that of light. These phenomena are unusual and not found before. The underlying signaling pathways are partially similar with that of light-induced phase delay at early night but are likely different from that of light in the aspect of retina-SCN neurotransmission. GHRP-6 also exerted a reversible immobilizing effect, and this action is not likely associated with its phase-delay effect. The study suggests an important role of GHSs in coordinating feeding, energy metabolism, and circadian clock and may help to unveil the roles of GHSs in the circadian physiology of humans and favor the designing of appropriate chronotherapeutic strategies. 
